Research programme: anticancer therapeutics - AuraZyme

Drug Profile

Research programme: anticancer therapeutics - AuraZyme

Alternative Names: Anticancer therapeutics research programme - AuraZyme; AZ-CINN 310; AZ-CINN targeted prodrugs research programme - AuraZyme; AZ-CINN TARPs research programme - AuraZyme

Latest Information Update: 09 Feb 2007

Price : $50

At a glance

  • Originator AuraZyme Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; Tubulin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 09 Feb 2007 Preclinical development is ongoing
  • 22 Sep 2003 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top